<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC4353274/results/search/disease/results.xml">
  <result pre="Canada Guidelines Guidance on the use of antiviral drugs for" exact="influenza" post="in acute care facilities in Canada, 2014–2015 StiverH GrantMD1EvansGerald"/>
  <result pre="to inform health care professionals of the increased risk for" exact="influenza" post="in long-term care facilities due to a documented mismatch"/>
  <result pre="the components chosen for this season’s vaccine and currently circulating" exact="influenza" post="strains. Adjusted recommendations for the use of antiviral drugs"/>
  <result pre="strains. Adjusted recommendations for the use of antiviral drugs for" exact="influenza" post="in the acute care setting for this season are"/>
  <result pre="management of patients in the acute care setting infected with" exact="influenza" post="viruses circulating in Canada during the 2014–2015 influenza season."/>
  <result pre="infected with influenza viruses circulating in Canada during the 2014–2015" exact="influenza" post="season. A. PROCESS STATEMENT The development of this updated"/>
  <result pre="of Canada regarding early data indicating a mismatch of the" exact="influenza" post="vaccine H3N2 component to an emerging H3N2 seasonal strain."/>
  <result pre="to 48 h of symptom onset to low-risk outpatients with" exact="influenza" post="(where placebo-controlled trials were ethically safe) have shown that"/>
  <result pre="investigating the efficacy of NIs in treating mild to moderate" exact="influenza" post="illness in out-patients have not adequately addressed the significantly"/>
  <result pre="3.6 days (5). Inhaled zanamivir shortened the duration of major" exact="influenza" post="symptoms by 3 days compared with placebo in individuals"/>
  <result pre="30 h (3). In low-risk outpatients, NI treatment of mild" exact="influenza" post="illness may be considered but is optional (6). On"/>
  <result pre="the other hand, observational cohort-controlled studies of patients with severe" exact="influenza" post="due to the H3N2 subtype and H1N1 pandemic subtype"/>
  <result pre="persons with no discernable risk factors. In the current 2014–2015" exact="influenza" post="season, A(H3N2) influenza has accounted for the majority of"/>
  <result pre="discernable risk factors. In the current 2014–2015 influenza season, A(H3N2)" exact="influenza" post="has accounted for the majority of influenza cases documented"/>
  <result pre="influenza season, A(H3N2) influenza has accounted for the majority of" exact="influenza" post="cases documented by testing. In addition, a significant antigenic"/>
  <result pre="significant antigenic drift has occurred in the majority of H3N2" exact="influenza" post="strains obtained from ill patients, resulting in a clinically"/>
  <result pre="in a clinically relevant mismatch between the predominant circulating H3N2" exact="influenza" post="virus and the H3N2 vaccine strain. The WHO Global"/>
  <result pre="System laboratories have tested &amp;gt;96,535 specimens: 23,421 were positive for" exact="influenza" post="viruses, of which 22,129 (94.5%) were typed as influenza"/>
  <result pre="for influenza viruses, of which 22,129 (94.5%) were typed as" exact="influenza" post="A and 1292 (5.5%) as influenza B. Of the"/>
  <result pre="(94.5%) were typed as influenza A and 1292 (5.5%) as" exact="influenza" post="B. Of the subtyped influenza A viruses, 163 (1.7%)"/>
  <result pre="A and 1292 (5.5%) as influenza B. Of the subtyped" exact="influenza" post="A viruses, 163 (1.7%) were influenza A (H1N1) pdm09,"/>
  <result pre="B. Of the subtyped influenza A viruses, 163 (1.7%) were" exact="influenza" post="A (H1N1) pdm09, and 9211 (98.3%) were influenza A"/>
  <result pre="(1.7%) were influenza A (H1N1) pdm09, and 9211 (98.3%) were" exact="influenza" post="A (H3N2) (9). Although the vaccine may still provide"/>
  <result pre="date, the majority of the predominating H3N2 virus isolates of" exact="influenza" post="are susceptible to oseltamivir and zanamivir. All isolates of"/>
  <result pre="of H1N1 are oseltamivir- and zanamivir-susceptible. Almost all isolates of" exact="influenza" post="B are also susceptible to oseltamivir and zanamivir. C."/>
  <result pre="WITH ILI TO AN ACUTE CARE FACILITY? During peaks of" exact="influenza" post="activity in the community, a case definition in older"/>
  <result pre="of 86% and a negative predictive value of 39.3% for" exact="influenza" post="in patients attending an outpatient clinic (10). Of course,"/>
  <result pre="Of course, these values vary depending on the prevalence of" exact="influenza" post="in the community relative to other respiratory infections. In"/>
  <result pre="community relative to other respiratory infections. In older patients with" exact="chronic obstructive pulmonary disease," post="who have been vaccinated for influenza, only the presence"/>
  <result pre="may account for those with non-influenza infection. The use of" exact="influenza" post="polymerase chain reaction (PCR) is preferred to direct fluorescent"/>
  <result pre="to its greater sensitivity. A nasopharyngeal swab is preferred for" exact="influenza" post="PCR testing, particularly if the patient requires hospital admission."/>
  <result pre="with mild illness without risk factors for severe or complicated" exact="influenza" post="with antiviral drugs is not recommended if &amp;gt;48 h"/>
  <result pre="patients on ventilators may not improve and continue to shed" exact="influenza" post="viruses for prolonged periods, even after five days on"/>
  <result pre="discussion of the appropriate antibiotic management of patients with suspected" exact="bacterial pneumonia" post="is beyond the scope of this document. However, if"/>
  <result pre="of the appropriate antibiotic management of patients with suspected bacterial" exact="pneumonia" post="is beyond the scope of this document. However, if"/>
  <result pre="with an acute respiratory infection on a background of an" exact="influenza" post="outbreak, and a chest radiograph demonstrates pulmonary infiltrates, primary"/>
  <result pre="influenza outbreak, and a chest radiograph demonstrates pulmonary infiltrates, primary" exact="influenza" post="or secondary bacterial pneumonia, or both, are possibilities. Primary"/>
  <result pre="a chest radiograph demonstrates pulmonary infiltrates, primary influenza or secondary" exact="bacterial pneumonia," post="or both, are possibilities. Primary influenza pneumonia typically presents"/>
  <result pre="influenza or secondary bacterial pneumonia, or both, are possibilities. Primary" exact="influenza" post="pneumonia typically presents with severe shortness of breath and"/>
  <result pre="or secondary bacterial pneumonia, or both, are possibilities. Primary influenza" exact="pneumonia" post="typically presents with severe shortness of breath and occurs"/>
  <result pre="both, are possibilities. Primary influenza pneumonia typically presents with severe" exact="shortness" post="of breath and occurs within one to three days"/>
  <result pre="illness with reappearance of fever after defervesence from a typical" exact="influenza" post="illness might represent a complicating secondary bacterial pneumonia. Bacterial"/>
  <result pre="from a typical influenza illness might represent a complicating secondary" exact="bacterial pneumonia." post="Bacterial pneumonia should be strongly suspected when a typical"/>
  <result pre="influenza illness might represent a complicating secondary bacterial pneumonia. Bacterial" exact="pneumonia" post="should be strongly suspected when a typical influenza illness"/>
  <result pre="pneumonia. Bacterial pneumonia should be strongly suspected when a typical" exact="influenza" post="illness is resolving, usually around the fifth day, and"/>
  <result pre="severely ill patients, appropriate antibiotics for community-acquired or nursing home-acquired" exact="pneumonia" post="should be instituted immediately, as well as NI antiviral"/>
  <result pre="infection control measures for the management of patients with suspected" exact="influenza" post="is beyond the scope of this document. However, the"/>
  <result pre="the following measures are generally employed. Patient isolation During an" exact="influenza" post="outbreak, all individuals with ILI admitted to the emergency"/>
  <result pre="PROPHYLAXIS FOR PATIENTS AND HCWs? Post-exposure prophylaxis: Secondary cases of" exact="influenza" post="in family members of an index case can be"/>
  <result pre="(oseltamivir) to 10 (zanamivir) days to reduce the chance of" exact="influenza" post="illness. This is especially important this influenza season in"/>
  <result pre="the chance of influenza illness. This is especially important this" exact="influenza" post="season in the face of the vaccine mismatch. Post-exposure"/>
  <result pre="influenza: A randomized controlled trialLancet200035518455010866439 2.collab: The MIST (Management of" exact="influenza" post="in the Southern Hemisphere Trialists) Study GroupRandomised trial of"/>
  <result pre="of efficacy and safety of inhaled zanamivir in treatment of" exact="influenza" post="A and B virus infectionsLancet19983521877819863784 3.HaydenFGOsterhausADMETreanorJJet al.Efficacy and safety"/>
  <result pre="the treatment of influenzaviris infectionsNew Engl J Med1997337874809302301 4.JeffersonTJonesMDoshiPSpencerEAOnakpoyaIHeneghanCJOseltamivir for" exact="influenza" post="in adults and children: Systematic review of clinical study"/>
  <result pre="5.AokiFYMacleodMDPaggiaroPet al.Early administration of oral oseltamivir increases the benefits of" exact="influenza" post="treatmentJ Antimicrob Ther2003511239 6.AokiFYAllenUDStiverHGLaverdièreMEvansGAThe use of antiviral drugs for"/>
  <result pre="Did Med Microbiol201324Suppl C1C15C 7.McGeerAGreenKPlevneshiAet al.Antiviral therapy and outcomes of" exact="influenza" post="requiring hospitalization in Ontario, CanadaClin Infect Dis20074515687518190317 8.LouieJKYangSAcostaMet al.Treatment"/>
  <result pre="8.LouieJKYangSAcostaMet al.Treatment with neuraminidase inhibitors for critically ill patients with" exact="influenza" post="(H1N1) pdmo9Clin Infect Dis2012551198120422843781 9.collab: World Health OrganizationInfluenza update1212015–"/>
  <result pre="update1212015– Update number 228. &amp;lt;www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en&amp;gt; (Accessed January 13, 2015). 10.BoivinGHardyITellierGMaziadeJPredicting" exact="influenza" post="infections during epidemics with the use of a clinical"/>
  <result pre="the use of a clinical case definitionClin Infect Dis2000311166911073747 11.NeuzilKMO’ConnorTZGorseGJNicholKLRecognizing" exact="influenza" post="in older patients with chronic obstructive pulmonary disease who"/>
  <result pre="case definitionClin Infect Dis2000311166911073747 11.NeuzilKMO’ConnorTZGorseGJNicholKLRecognizing influenza in older patients with" exact="chronic obstructive pulmonary disease" post="who have received influenza vaccineClin Infect Dis2003361697412522748 12.BisnoALGriffinJPVan EppsKANiellHBRytelMWPneumonia"/>
  <result pre="older patients with chronic obstructive pulmonary disease who have received" exact="influenza" post="vaccineClin Infect Dis2003361697412522748 12.BisnoALGriffinJPVan EppsKANiellHBRytelMWPneumonia and Hong Kong influenza:"/>
  <result pre="for oral suspension&amp;lt;www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021246Orig1s045_021087Orig1s062_tamiflu_toc.cfm&amp;gt; (Accessed January 13, 2015). 16.HalloranMEHaydenFGYangYLonginiIMJrMontoASAntiviral effects on" exact="influenza" post="viral transmission and pathogenicity: Observation-based trialsAm J Epidemiol20071652122117088311 TABLE"/>
  <result pre="trialsAm J Epidemiol20071652122117088311 TABLE 1 Oseltamivir and zanamivir treatment of" exact="influenza" post="Updated from: The use of antiviral drugs for influenza:"/>
  <result pre="antivirals are not authorized for the routine treatment of seasonal" exact="influenza" post="illness in infants &amp;lt;1 year of age. Such use"/>
  <result pre="weight is not known, dosing by age for treatment of" exact="influenza" post="(give two doses per day) or prophylaxis (give one"/>
  <result pre="25 mg per dose. 3.It is strongly suggested that an" exact="infectious disease" post="physician or clinical pharmacist be consulted in the case"/>
  <result pre="not recommended for persons with chronic respiratory diseases such as" exact="asthma" post="or chronic obstructive pulmonary disease that increase the risk"/>
  <result pre="for persons with chronic respiratory diseases such as asthma or" exact="chronic obstructive pulmonary disease" post="that increase the risk of bronchospasm. TABLE 2 Recommended"/>
  <result pre="a framework for guidance, it is strongly suggested that an" exact="infectious disease" post="physician, a specialist in renal insufficiency or clinical pharmacist"/>
 </snippets>
</snippetsTree>
